Literature DB >> 28091934

Roles of Plasmablasts and B Cells in IgG4-Related Disease: Implications for Therapy and Early Treatment Outcomes.

Marco Lanzillotta1, Emanuel Della-Torre1, John H Stone2.   

Abstract

High serum IgG4 concentrations are a striking feature of many patients with IgG4-related disease (IgG4-RD). Blood levels of IgG4 often reach ten, twenty, and even thirty or more times higher than the upper limit of normal. Under the proper clinical circumstances, the finding of an elevated serum IgG4 concentration serves as a useful biomarker for the diagnosis of this condition. This serum IgG4 elevation quickly called attention to the possibility of therapies targeting cells of the B lymphocyte lineage. In addition, a greater understanding of the cellular mechanisms that underpin IgG4-RD has identified peripheral blood plasmablasts as a promising biomarker for this disease. The roles of plasmablasts and B cells in IgG4-RD are discussed in this chapter.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28091934     DOI: 10.1007/82_2016_58

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  13 in total

Review 1.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

2.  Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Richard J Nowak; Kevin C O'Connor
Journal:  JCI Insight       Date:  2017-09-07

3.  B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease.

Authors:  Emanuel Della-Torre; Elena Rigamonti; Cory Perugino; Simona Baghai-Sain; Na Sun; Naoki Kaneko; Takashi Maehara; Lucrezia Rovati; Maurilio Ponzoni; Raffaella Milani; Marco Lanzillotta; Vinay Mahajan; Hamid Mattoo; Ivan Molineris; Vikram Deshpande; John H Stone; Massimo Falconi; Angelo A Manfredi; Shiv Pillai
Journal:  J Allergy Clin Immunol       Date:  2019-07-15       Impact factor: 10.793

Review 4.  [Immunoglobulin-G4-related disease].

Authors:  Jasper F Nies; Martin Krusche
Journal:  Z Rheumatol       Date:  2022-06-29       Impact factor: 1.530

Review 5.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

6.  Combined membranous nephropathy and tubulointerstitial nephritis as a rare renal manifestation of IgG4-related disease: a case-based literature review.

Authors:  Wei Zhang; Jeffrey H Glaze; David Wynne
Journal:  CEN Case Rep       Date:  2018-02-01

7.  Sustained clinical response after single course of rituximab as first-line monotherapy in adult-onset asthma and periocular xanthogranulomas syndrome associated with IgG4-related disease: A case report.

Authors:  Giovanni Pomponio; Diletta Olivari; Massimo Mattioli; Alessia Angeletti; Giulia Rossetti; Gaia Goteri; Armando Gabrielli
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

8.  IgG4-Related Disease of the Oral Cavity. Case Series from a Large Single-Center Cohort of Italian Patients.

Authors:  Andrea Rampi; Marco Lanzillotta; Gaia Mancuso; Alessandro Vinciguerra; Lorenzo Dagna
Journal:  Int J Environ Res Public Health       Date:  2020-11-05       Impact factor: 3.390

9.  Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients.

Authors:  Umberto Basile; Mariapaola Marino; Cecilia Napodano; Krizia Pocino; Paolo Emilio Alboini; Francesca Gulli; Amelia Evoli; Carlo Provenzano; Emanuela Bartoccioni
Journal:  J Immunol Res       Date:  2018-03-25       Impact factor: 4.818

10.  B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma.

Authors:  Claudia Minici; Elena Rigamonti; Marco Lanzillotta; Antonella Monno; Lucrezia Rovati; Takashi Maehara; Naoki Kaneko; Vikram Deshpande; Maria Pia Protti; Lucia De Monte; Cristina Scielzo; Stefano Crippa; Paolo Giorgio Arcidiacono; Erica Dugnani; Lorenzo Piemonti; Massimo Falconi; Shiv Pillai; Angelo A Manfredi; Emanuel Della-Torre
Journal:  Oncoimmunology       Date:  2020-07-16       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.